logo-loader

Outlook Therapeutics over 50% enrolled in clinical study to treat wet AMD

Published: 06:52 13 Jan 2019 AEDT

Outlook Therapeutics (NASDAQ:OTLK) CEO Larry Kenyon sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

11 hours, 43 minutes ago